Neurodivergent traits in childhood double the risk of chronic disabling fatigue by age 18, with inflammation playing a significant mediating role. This highlights the importance of addressing inflammatory markers in managing the health of neurodivergent individuals.
PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney | Psychedelic Invest
PharmAla Biotech Holdings Inc. (CSE: MDMA / OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA),